EP Patent status and claim 1 of UC Berkeley‘s CRISPR-Cas9 Patents.

執筆用メモ

UCBの欧州特許

一本鎖型については本命、欧州では二本鎖型を狙った出願を既に権利化済。

EP2800811B：口頭審理未定（補正クレーム提出済（2018/10/25））

1.  A method of modifying a target DNA, the method comprising contacting the target DNA with a complex comprising:

  (a) a Cas9 polypeptide and

  (b) a single-molecule DNA-targeting RNA comprising:

    (i) a DNA-targeting segment comprising a nucleotide sequence that is complementary to a sequence in the target DNA, and

    (ii) a protein-binding segment that interacts with said Cas9 polypeptide, wherein the protein-binding segment comprises two complementary stretches of nucleotides that hybridize to form a double stranded RNA (dsRNA) duplex,

   wherein said two complementary stretches of nucleotides are covalently linked by intervening nucleotides,

   wherein said contacting is in vitro or in a cell ex vivo; and

   wherein said modifying is cleavage of the target DNA.

・一本鎖型の基本特許

EP3241902B：異議申立あり

1.  A composition comprising:

  (a) a chimeric Cas9 protein, or a polynucleotide encoding said chimeric Cas9 protein,

     wherein the chimeric Cas9 protein comprises a modified Cas9 protein having reduced nuclease activity compared to the corresponding wild-type Cas9, and comprises a heterologous polypeptide that:

    (i) has DNA modifying activity, or

    (ii) exhibits the ability to increase or decrease transcription, or

    (iii) has enzymatic activity that modifies a polypeptide associated with DNA; and

  (b) a DNA-targeting RNA, or one or more DNA polynucleotides encoding said DNA-targeting RNA, wherein said DNA-targeting RNA comprises:

    (i) a DNA-targeting segment comprising a nucleotide sequence that is complementary to a sequence in a target DNA, and

    (ii) a protein-binding segment that interacts with said chimeric Cas9 protein,

    wherein the protein-binding segment comprises two complementary stretches of nucleotides that hybridize to form a double stranded RNA (dsRNA) duplex.

・ニッカーゼ型Cas9およびdCas9をカバーする形態。

・ガイド鎖は、一本鎖型に限定されず、二本鎖型を含む。

・神大　西田先生のバイオパレットは、sgRNA+dCas9-AIDを使用しているはずなので、(a)(i)で引っかかってる可能性。